Pennsylvania, USA-based CNS specialist Vallon Pharmaceuticals (Nasdaq: VLON) has been dealt a body blow by the failure of its pivotal SEAL study in ADHD.
Top-line results show the trial, which is evaluating a special abuse-deterrent formulation of immediate release dextroamphetamine, missed its primary endpoint.
In New York, shares in the company fell by around two-thirds on Monday, following the news.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze